

This Live Activity has been approved for
22.75 AMA PRA Category I Credits(s)[™]

Ten (10) FREE SAMs for
Maintenance of Certification

RIISING TO NEW HEIGHTS

The Radiation Oncology Summit

RADIATION *The* ONCOLOGY

SUMMIT

March

ACRO 2019

7-9

Hilton Orlando Lake Buena Vista

Orlando, Florida

SPECIAL FEATURES

- Disease Site-Based Scientific Program With Top Faculty
- Special Session on the Life and Legacy of Dr. Luther Brady
- Business and Economics of Radiation Oncology Practice Session
- Resident & New Practitioner Symposia
- Networking Opportunities
- Women in Radiation Oncology Forum
- MEET (Meet Excellent Educators & Teachers)
- Diversity & Inclusion Forum
- Oral Papers Sessions
- Posters Sessions & Walk
- Locum Tenens Forum
- Fun Run/Walk
- Exhibition Hall

Joint Providership of



American College of
RADIATION ONCOLOGY
Integrating Science and Technology into Patient Care



Community
Health Network



Welcome!

Last year we changed the name of our annual meeting to *The Radiation Oncology Summit* - and it worked. A summit is a meeting where top people in a field gather together to learn from each other and improve their specialty. That's what happened.

ACRO's annual meetings have always been a relaxing and friendly experience, in contrast to so many other big national conferences where the pace is frenetic. At ACRO's *Summit*, attendees have the time to talk to each other and to the invited speakers in an environment of mutual respect and learning. And from social activities and other networking opportunities, education also occurs outside the lecture hall. Our goal is to make sure you leave the *Summit* with the latest knowledge and skills that can be implemented immediately as soon as you return to your practice.

In addition, most CME plenary sessions are eligible for a SAM to cover your ABR MOC requirement for a full year - all in one place and at no extra cost. We look forward to meeting you at this *Summit*.

Eduardo Fernandez MD, PhD, FACRO
President



Sheila Rege MD, FACRO
Vice President and
General Program Chair



Jason Efstathiou MD, DPhil
Co-Chair, Scientific
Program Committee



Steven Finkelstein MD, FACRO
Co-Chair Scientific
Program Committee



— Friday, March 8 • 1:15 - 1:45 pm —

Special Remembrance:

The Life and Legacy of Dr. Luther Brady



Moderator: Eduardo Fernandez MD, PhD, FACRO

Sucha Asbel MD, FACRO
Cooper University Health Care, Mount Laurel, NJ

Joanne Dragun MD, FACRO
21st Century Oncology, Jacksonville, FL

Dennis Galinsky MD, FACRO
Berwyn Radiation Oncology, Berwyn, IL

ACRO Board of Chancellors**Chairman**

James Welsh MD, FACRO

President

Eduardo Fernandez MD, PhD, FACRO

Vice President

Sheila Rege MD, FACRO

Secretary/Treasurer

William Noyes MD, MBA, FACRO

Chancellors

Joanne Dragun MD, FACRO

Steven Finkelstein MD, FACRO

Arve Gillette MD, FACRO

Dwight Heron MD, FACRO

Shane Hopkins MD, FACRO

Charles Thomas II MD, FACRO

Catheryn Yashar MD, FACRO

2019 Annual Meeting Committee**General Chair**

Sheila Rege MD, FACRO

Scientific Program Committee**Co-Chairs**

Jason Efstathiou MD, DPhil

Steven Finkelstein MD, FACRO

Development Committee Chair

Charles Thomas II MD, FACRO

CME Coordinator

Valerie Brown CPS

2019 Scientific Program Committee

Parul Barry MD

Valerie Brown CPS

Michael Chuong MD

Steven Finkelstein MD, FACRO (Co-Chair)

Jason Efstathiou MD, DPhil (Co-Chair)

Courtney Hentz MD

Brian Lally MD

Shannon MacDonald MD

Jessica Moore MD

Brandi Page MD

Charles Simone II MD

Tarita Thomas MD

Stephanie Weiss MD

2019 Abstract Reviewers

Michael Chuong MD

Steven Feigenberg MD

Steven Finkelstein MD, FACRO

Courtney Hentz MD

Krisha Howell MD

Brian Lally MD

John Lukens MD

Lawrence Kleinberg MD, FACRO

Sameera Kumar MD

Virginia Osborn MD

Brandi Page MD

Jessica Schuster MD

Neil Taunk MD

Tarita Thomas MD

Stephanie Weiss MD

Learning Objectives:

At the conclusion of the conference attendees should be able to:

1. Implement the latest scientific advances into evidenced based standards of care in radiation oncology.
2. Demonstrate competence in billing and coding for radiation oncology treatment in the face of increased governmental regulation and financial cuts.
3. Evaluate the treatment of acute and long-term complications of radiation therapy for Breast, CNS, Endometrial, Gastrointestinal, Genitourinary, Head & Neck, Lymphoma, Sarcoma, and Thoracic Malignancies in order to improve patient outcomes.
4. Describe and apply state of the art treatment management for Breast, CNS, Endometrial, Gastrointestinal, Genitourinary, Head & Neck, Lymphoma, Sarcoma, and Thoracic Malignancies.

5. Interpret the changing political, economic, and regulatory health care environment in order to survive the year ahead.
6. Link clinical/practice updates to address clinical controversies in tumor boards and grand rounds.

Accreditation, CME Credits and Disclosure:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Indiana State Medical Association (ISMA) through the joint providership of Community Health Network and the American College of Radiation Oncology. Community Health Network is accredited by ISMA to provide continuing medical education for physicians.

Community Health Network designates this live educational activity for a maximum of **22.75 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

While offering the CME credit above, this activity is not intended to provide extensive training in the field. ADA accommodations are available upon request.

Community Health Network has implemented a process whereby everyone who is in a position to control the content of an educational activity has disclosed all relevant financial relationships, with any commercial interest. In addition, should it be determined that a conflict of interest exists as a result of a financial relationship, it will be resolved prior to the activity.

ACRO 2019 FACULTY



Robert Amdur MD
University of Florida, Gainesville, FL



Vinai Gondi MD
Northwestern Medicine Cancer Center, Warrenville, IL



Matthew Harkenrider MD
Loyola University, Maywood, IL



Brian Lally MD
University of Pennsylvania, Philadelphia, PA



Christopher Crane MD
Memorial Sloan Kettering Cancer Center, New York, NY



David Grosshans MD, PhD
MD Anderson Cancer Center, Houston, TX



Richard Hausmann PhD
Elekta, Stockholm, Sweden



Richard Levy PhD
Palo Alto, CA



Ronald DiGiamio MBA
Revenue Cycle Inc., Cedar Park, TX



Bruce Haffty MD
Rutgers Cancer Institute, New Brunswick, NJ



Courtney Hentz MD
Loyola University Medical Center, PGY-5, Chicago, IL



J. Nicholas Lukens
University of Pennsylvania School of Medicine, Philadelphia, PA



Bree Eaton MD
Emory University, Atlanta, GA



Daniel Hamstra MD, PhD
Oakland University, Dearborn, MI



Jaraslow Hepel MD, FACRO
Rhode Island Hospital, Providence, RI



Shannon MacDonald MD
MGH/Harvard University, Boston, MA



Erin Gillespie MD
Memorial Sloan Kettering Cancer Center, New York, NY



ACRO 2019 FACULTY



Barbara McAneny MD
American Medical Association,
Chicago, IL



Brandi Page MD
Johns Hopkins Medicine,
Bethesda, MD



Sheila Rege MD, FACRO
Northwest Cancer Clinic,
Kennewick, WA



Neha Vapiwala MD
University of Pennsylvania,
Philadelphia, PA



Jason McKitrick MBA
Liberty Partners Group,
Washington, D.C.



Parag Parikh MD
Henry Ford Health System,
Detroit, MI



Chad Rusthoven MD
University of Colorado, Aurora, CO



Dow Wilson MBA
Varian Medical Systems,
Palo Alto, CA



Jeff Michalski MD
Washington University School of
Medicine, St. Louis, MO



Asal Rahimi MD
University of Texas Southwestern,
Dallas, TX



Charles Simone MD
New York Proton Center,
Manhattan, NY



Karen Winkfield MD, PhD
Wake Forest University,
Winston-Salem, NC



Benjamin Movsas MD
Henry Ford Cancer Institute,
Detroit, MI



Marcus Randall MD
University of Kentucky,
Lexington, KY




Jonathan Strauss MD, MBA
Northwestern Medicine,
Chicago, IL



Andrew Woods Esq
Liberty Partners Group,
Washington D.C.



Catheryn Yashar MD, FACRO
University of California San Diego,
La Jolla, CA



ACRO 25-YEAR MEMBERS

Andre Abitbol MD, FACRO
 Jeffrey Acker MD
 Scot Ackerman MD
 Mark Alden MD, FACRO
 Thomas Anderson DO, FACRO
 Steven Anolik MD
 Mitchell Anscher MD, FACRO
 Sucha Asbell MD, FACRO
 Azhar Awan MD
 Sanjeev Bahri MD, FACRO
 Franklin Banker MD
 Jerry Barker MD, FACRO
 Robert Bertoli MD
 David Beyer MD, FACRO
 Inder Bhutiani MD
 Stuart Blacher MD
 Tarlton Blair PhD, MD, FACRO
 Barry Blyton MD
 Luther Brady MD, FACRO
 Alice Bulger MBA
 David Butler MD
 Richard Byrnes MD, FACRO
 David Catalano MD, FACRO
 Alex Chen MD, FACRO
 Luci Chen MD, FACRO
 Judy Chin MD, FACRO
 Douglas Ciuba MD, FACRO
 Henry Cline MD, FACRO
 Brad Cohen MD
 Martin Colman MD
 James Corwin MD
 Gregory Cotter MD, FACRO
 Wayne Court PhD, MD, FACRO
 John Crawford MD
 James Currier MD, FACRO
 Mark D'Andrea MD, FACRO
 Pankaj Dalal MD
 Frank Dancuart MD, FACRO
 Kishore Dass MD
 D. Jeffrey Demanes PhD, MD, FACRO
 Paul DeMare MD
 Richard Deming MD, FACRO
 Melvin Deutsch MD
 Richard Diaz MD, FACRO
 Gregg Dickerson MD, FACRO
 Daniel Dosoretz MD, FACRO
 Joanne Dragun MD, FACRO
 Raymond Dugal MD
 Michael Durci MD
 John Edlund MD
 John Einck MD, FACRO
 Rodney Ellis MD
 Bahman Emami MD, FACRO
 Kirsten Erickson MD, FACRO
 Eduardo Fernandez MD, PhD, FACRO
 James Flynn MD, FACRO

Thomas Fogel MD, FACRO
 James Fontanesi MD
 Arthur Frazier MD, FACRO
 Donald Fuller
 John Funke MD, FACRO
 Dennis Galinsky MD, FACRO
 Scott Gasiorek MD, FACRO
 James Giebink MD, FACRO
 Betty Gil MD
 Arve Gillette MD, FACRO
 Juan Godinez MD
 Robert Goebel MM, JD, MD, FACRO
 Joel Greenberger MD, FACRO
 Daniel Haraf MD
 Lowndes Harrison MD, FACRO
 Robert Haselow MD
 Mary Hebert MD, FACRO
 William Helvie MD, FACRO
 Jeffrey Herman MD
 Robert Hesselgesser MD
 Steven Hightower MD, FACRO
 Jack Hong MD, FACRO
 David Hurst MD, DMD, FACRO
 Tahir Ijaz MD, FACRO
 Joseph Jenrette MD, FACRO
 Gregory Jones MD
 Joseph Kaczor MD
 James Kane, Jr. MD, FACRO
 Michael Katin MD, FACRO
 Nathan Kaufman MD, FACRO
 Guy Kedziora MD, FACRO
 Joan Keit MD, FACRO
 Shiv Khandelwal MD, FACRO
 Monica Khanna MD
 Krystyna Kiel MD
 James Kinard PhD, MD, FACRO
 Gordon Koltis MD, FACRO
 John Kosiak MD
 Bradley Kramer MD
 John Kresl MD, PhD, FACRO
 Roger Krueger MBA
 Michael Kuettel PhD, MD, FACRO
 Anand Kuruvilla MD, FACRO
 Roby Lal DO
 Kenneth Lam MD, FACRO
 Michael Lambo MD, FACRO
 Frank Lamm MD, FACRO
 Steven Lester MD, FACRO
 Kathryn Lewis MD, FACRO
 Vasudha Lingareddy MD, FACRO
 Roberto Lipsztein MD
 Jeffrey Lopez MD
 Ricardo Lopez-Mujica MD, FACRO
 Hsin Lu MD
 Ronald Lutsic DO
 Gregory Maggass MD, FACRO

R. Mantravadi MD, FACRO
 Michael Marchese MD, FACRO
 John Marvel MD, FACRO
 Dean Mastras MD
 Charles Mateskon MD
 Byron May MD
 Bruce McAllister MD, MS, FACRO
 Dale McCord MD
 James McGee MD, FACRO
 William McGinnis MD
 Patrick McKenna MD
 Gerald Medwick DO, FACRO
 Allen Meek MD
 Ruby Meredith MD, PhD, FACRO
 Gregory Merrick MD
 Bruce Merwin MD, FACRO
 Paul Miller MD
 Terence Moore MD
 John Mullen MD
 Duane Myers MD
 Ranjeev Nanda MD, FACRO
 Ernest Ngo MD, FACRO
 Timothy Nichols MD
 John Norlund MD
 Louis Novak MD, FACRO
 William Noyes MBA, MD, FACRO
 David Owens MD, FACRO
 Laeton Pang MD, FACRO
 Shyam Paryani MD, FACRO
 Pradip Pathare MD, FACRO
 Claudia Perez-Tamayo MD, FACRO
 William Podolsky MD, PhD
 Farida Rajput MD, FACRO
 Susan Rakfal MD, FACRO
 Nilam Ramsinghani MD, FACRO
 Yallapragada Rao MD, FACRO
 Sarada Reddy MD, FACRO
 Sheila Rege MD, FACRO
 John Reilly MD
 Lillian Rinker MD
 Louis Rivello MD
 David Rohde MD
 Alfred Rosenbaum MD, FACRO
 Robert Rostock MD, FACRO
 James Rubenstein MD, FACRO
 Jose Santana-Rabell MD, FACRO
 Paul Schilling MD, FACRO
 Alvin Schlichtemeier MD
 Philip Schneider MD, FACRO
 Donald Schwarz MD, FACRO
 Carol Scicutella DO, FACRO
 Robert Scruggs MD
 Kimberly Sevensing
 Armen Shahbazian MD
 John Shaw MD, FACRO
 Sunderam Shetty MD, FACRO

Lawrence Shombert MD, FACRO
 Dennis Shrieve MD, PhD
 Khalid Siddiqui MD, FACRO
 Larry Silverman MD
 Michael Skowronski MS, FACRO
 William Small, Jr. MD, FACRO
 Damon Smith MD, FACRO
 Gerald Sokol MD
 Michael Sorensen MD
 Wayne Spears MD
 T. Spencer MD, FACRO
 John Spera MD, FACRO
 Stephen Springate
 Jerome Spunberg MD, FACRO
 Baldassarre Stea PhD, MD
 Jonathan Stella MD
 James Stevens MD, FACRO
 Gordon Stillie MBA, DO, FACRO
 Thomas Stoffel MD, FACRO
 Andrejs Strauss MD
 Revathi Swaminathan MD
 A.M. Nisar Syed MD, FACRO
 Michael Tay MD
 Eric Taylor MD, FACRO
 John Taylor MD, FACRO
 Michael Taylor MD, FACRO
 Ferial Tewfik PhD, MD
 Hamed Tewfik MD
 Harish Thakrar MD, FACRO
 John Thomas MD, FACRO
 Charles Thomas II MD, FACRO
 Donald Tilton DO
 Robert Tomchuck DO
 William Tomlinson MD, FACRO
 Paul Treadwell MD
 Mark Trombetta MD, FACRO
 Jefferson Trupp MD, FACRO
 Eric Van Rooy MD
 Frank Vicini MD
 Phillip Vigneri DO, FACRO
 Vitune Vongtama MD
 David Wahl MD, FACRO
 Wesley Walker MD
 David Wazer MD, FACRO
 Benjamin West MD
 Barry Wilcox MD, FACRO
 Steven Wilson MD
 Michael Wing MD
 Ben Wright MD
 Theodore Yaeger MD
 Mohammed Zahra MD, FACRO
 Andrej Zajac MD
 Kenneth Zeitzer MD, FACRO

ACRO 2019 AT-A-GLANCE

WEDNESDAY, MARCH 6

1:00 – 6:00 pm	Palm Foyer	Registration Open
2:00 – 5:00 pm	Palm 5	Updates & Dilemmas in Billing and Coding

THURSDAY, MARCH 7

6:30 am – 6:00 pm	Palm Foyer	Registration Open
7:30 – 8:15 am	Palm 1	Breakfast with the President of the AMA (21st Century)
8:15 – 8:30 am	Palm 1	Presidential Welcome & Meeting Overview
8:30 – 10:00 am	Palm 1	Ablative Radiotherapy for Liver and Pancreas Cancers: Why, When, and How
10:00 – 10:40 am	Palm 2-3-4	Exhibits/Break
10:45 am – 12:00 pm	Palm 1	Contouring Symposium
12:00 – 1:00 pm	Palm 5	ViewRay Satellite Symposium
12:00 – 1:15 pm	Palm 2-3-4	Lunch in Exhibit Hall
	Narcissus/Orange	Sucha Asbell Women in Radiation Oncology Forum
1:15 – 2:45 pm	Palm 1	Improving the Paradigms in Lung Cancer
2:45 – 3:30 pm	Palm 2-3-4	Exhibits/Break
3:00 – 5:00 pm	Palm 1	PCI: To Radiate or Not to Radiate
5:00 – 6:00 pm	Palm 1	Oral Presentations
	Narcissus/Orange	New Practitioner Symposium
6:15 – 7:45 pm	Azalea/Begonia	Standards Committee Meeting
	Poinsettia/Quince	Membership Committee Meeting
	Veranda Room	New Practitioner Committee Meeting
6:30 – 7:30 pm	Palm 5	Sirtex Satellite Symposium

FRIDAY, MARCH 8

6:30 am – 6:00 pm	Palm Foyer	Registration Open
6:45 – 7:30 am	Palm Foyer	Radiating Hope Fun Run/Fun Walk!
7:00 – 8:00 am	Palm 5	Bayer Satellite Symposium
	Palm 2-3-4	Breakfast in Exhibit Hall
	Veranda	Diversity and Inclusion Breakfast
8:00 – 9:30 am	Palm 1	Exploring the Changing Landscape for High-Risk and Advanced Prostate Cancer
9:30 – 10:15 am	Palm 2-3-4	Exhibits/Break

10:15 – 11:45 am	Palm 1	Evolving Paradigms in Treating Breast Cancer With Radiotherapy
12:00 – 1:00 pm	South Ballroom	Lunch with Presentations: CEO Vision for the Future (Varian and Elekta)
1:15 – 1:45 pm	Palm 1	The Life and Legacy of Dr. Luther Brady
1:45 – 2:15 pm	Palm 1	Keynote Address
2:15 – 2:45 pm	Palm 1	ACRO Awards Ceremony
2:45 – 3:00 pm	Palm Foyer	Break
3:00 – 5:00 pm	Palm 1	The Business & Economics of Radiation Oncology Practice
2:45 – 5:15 pm	Narcissus/Orange	Resident Symposium
5:15 – 6:45 pm	Poinsettia	Government Relations & Economics Committee
5:15 – 7:15 pm	Narcissus/Orange	New Practitioner & Resident Symposium / MEET featuring Quizzo (Revenue Cycle)
6:00 – 7:00 pm	Palm 5	Varian Satellite Symposium
7:00 – 8:00 pm	Poolside or Palm 2-3-4	President's Reception

SATURDAY, MARCH 9

7:30 am – 2:00 pm	Palm Foyer	Registration Open
7:30 – 9:00 am	Narcissus/Orange	Resident & New Practitioner Symposium - "Street Smarts"
8:00 – 9:00 am	Palm 5	Novocure Satellite Symposium
	Veranda Room	Scientific Program Committee Meeting
9:00 – 10:15 am	Palm 1	Challenging Topics in Head and Neck Cancer
10:15 – 10:45 am	Palm 2-3-4	Break with Posters
10:45 am – 12:00 pm	Palm 1	Curing Endometrial Cancer, One Gray at a Time
12:00 – 1:30 pm	Palm 2-3-4	Lunch with Posters/Poster Walk
12:30 – 1:30 pm	Palm 5	Locum Tenens Forum
1:30 – 2:45 pm	Palm 1	Lymphoma in Adults, Adolescents and Children
2:45 – 3:00 pm	Palm Foyer	Break
3:00 – 4:15 pm	Palm 1	Sarcoma in Adults, Adolescents and Children
4:15 – 5:30 pm	Palm 1	Oral Presentations
5:30 pm	ACRO 2019 Adjourns	
5:30 – 7:30 pm	Narcissus	ACRO Board of Chancellors Meeting

RISING TO NEW HEIGHTS



WEDNESDAY, MARCH 6

1:00 - 6:00 pm • Palm Foyer

Registration Open

2:00 - 5:00 pm • Palm 5

Updates & Dilemmas in Billing and Coding

Ron DiGiaino MBA – Revenue Cycle Inc., Austin, TX

THURSDAY, MARCH 7

6:30 am - 6:00 pm • Palm Foyer

Registration Open

7:30 - 8:15 am • Palm 1

Breakfast with the President of the AMA

Barbara McAneny, MD – American Medical Association, Chicago, IL

Hosted by 21st Century Oncology

8:15 - 8:30 am • Palm 1

Presidential Welcome & Meeting OverviewEduardo Fernandez MD, PhD, FACRO – President
Jason Efstathiou MD, DPhil, & Steven Finkelstein MD, FACRO
– Scientific Program Committee Co-Chairs8:30 - 10:00 am • Palm 1 • **FREE SAM****Ablative Radiotherapy for Liver and Pancreas Cancers: Why, When, and How**

Moderator: Michael Chuong

- **Ablative Radiation for Locally Advanced Pancreatic Cancer Using (Cone Beam) CT**
Christopher Crane – Memorial Sloan Kettering Cancer Center, New York, NY
- Parag Parikh – Henry Ford Health System, Detroit, MI

10:00 am • Palm 2-3-4

Exhibits Open

10:00 - 10:40 am • Palm 2-3-4

Exhibits/Break10:45 am - 12:00 pm • Palm 1 • **FREE SAM****Contouring Symposium**

Erin Gillespie – Memorial Sloan Kettering Cancer Center, New York, NY

Matthew Harkenrider – Loyola University, Maywood, IL

J. Nicholas Lukens – University of Pennsylvania School of Medicine, Philadelphia, PA

Jeff Michalski – Washington University School of Medicine, St. Louis, MO

12:00 - 1:15 pm • Palm 2-3-4

Lunch in Exhibit Hall

THURSDAY CONTINUED

12:00 - 1:00 pm • Palm 5

ViewRay Satellite Symposium (not CME Eligible)

See page 15 for more information.

- **ViewRay MRIdian Linac: From Startup to On-Table Adaptive Cases**
Michael Chuong MD

12:00 - 1:15 pm • Narcissus/Orange

Sucha Asbell Women in Radiation Oncology Forum

- Join your colleagues for a networking lunch.

1:15 - 5:15 pm • Azalea/Begonia

Practice Interviews

- Sign up at registration desk by 10:00 am

1:15 - 2:45 pm • Palm 1 • **FREE SAM**

Improving the Paradigms in Lung Cancer

Moderators: Isabelle Choi, Steven Feigenberg

- **Development of a Community-Based Pulmonary Nodule Clinic**
Brian Lally – University of Pennsylvania, Philadelphia, PA
- **Advanced Technologies in Locally Advanced Non-Small Cell Lung Cancer: IGRT, IMRT, and Proton Therapy**
Charles Simone – New York Proton Center, New York, NY
- **Small Cell Lung Cancer: Past, Present, Future**
Benjamin Movsas – Henry Ford Cancer Institute, Detroit, MI

2:45 - 3:30 pm • Palm 2-3-4

Exhibits/Break

3:00 - 5:00 pm • Palm 1 • **FREE SAM**

PCI: To Radiate or Not to Radiate

Moderators: Ranh Voong, Stephanie Weiss

- **Evidence For and Against PCI**
Chad Rusthoven – University of Colorado, Aurora, CO
- **Hippocampal Sparing in Small Cell Lung Cancer**
Vinai Gondi – Northwestern Medicine Cancer Center, Warrenville, IL
- **Toxicity of PCI**
David Grosshans – MD Anderson Cancer Center, Houston, TX

5:00 - 6:00 pm • Palm 1

Oral Presentations

Moderator: Colette Shen

- **A Survey of Understanding and Perceptions of Palliative Care in Radiation Oncology**
Jill Remickⁱ, Emily Kowalskiⁱ, Erica Glassⁱ, Charles Simoneⁱ, Pranshu Mohindraⁱ
ⁱ University of Maryland Department of Radiation Oncology, Baltimore, MD
- **Platelet-Lymphocyte and Lymphocyte-Monocyte Ratio Association with Vertebral Body Irradiation and Disease Progression in Esophageal Chemoradiotherapy**
Alexander Sherryⁱ, Neil Newmanⁱⁱ, Joshua Andersonⁱ, Evan Osmundsonⁱⁱ
ⁱ Vanderbilt University School of Medicine, Nashville, TN
ⁱⁱ Vanderbilt University Medical Center, Nashville, TN
- **Development of an Early Stage Breast Cancer Episodic Payment in Radiation Oncology**
Mark Waddleⁱ, Laura Vallowⁱ, Launia Whiteⁱⁱ, James Naessensⁱⁱ, Aaron Spauldingⁱⁱ, Robert Millerⁱ
ⁱ Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL
ⁱⁱ Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL
- **Gleason Grade Group Prediction for Prostate Cancer Using a Convolutional Neural Network Pretrained on Lesion and Normal Tissue Patches**
Joon Leeⁱ, Weiwei Zongⁱ, Hassan Bagher-Ebadianⁱ, Ning Wenⁱ
ⁱ Henry Ford Hospital, Detroit, MI

5:00 - 6:00 pm • Narcissus/Orange

New Practitioner Symposium

Moderator: Brandon Mancini

- Program features panel of chairs of departments to offer insights and answer your questions about steps to a successful academic career, suggestions for facilitating promotion, how to become involved within the field of Radiation Oncology, and much more. Panelists will include: A.J. Mundt, University of San Diego; Ben Movsas MD, Henry Ford Cancer Institute; and Bruce Haffty MD, Rutgers Cancer Institute.

6:15 - 7:45 pm • Various Rooms (see page 7)

Committee Meetings

- Standards • Membership • New Practitioner

6:30 - 7:30 pm • Palm 5

Sirtex Satellite Symposium (not CME Eligible)

See page 15 for more information.

- **Use of Y-90 Alone and with External Beam Radiotherapy for Unresectable Hepatic Tumors**
Andrew Kennedy, MD

FRIDAY, MARCH 8

6:30 am - 6:00 pm • Palm Foyer

Registration Open

6:45 - 7:30 am • Palm Foyer

Radiating Hope Fun Run/Fun Walk!

Organizer: Brandi Page

7:00 - 8:00 am • Veranda Room

Diversity and Inclusion Breakfast

Moderator: Karen Winkfeld

- It is an exciting time in the field of radiation oncology as we are evolving into a diverse group of physicians. Diversity represents the full spectrum of human demographic differences -- race, religion, gender, sexual orientation, age, socio-economic status or physical disability. Inclusion refers to a cultural and environmental feeling of belonging. Join colleagues for an informal conversation over breakfast and coffee to discuss our vision and strategies. Everyone is welcome to participate.

7:00 - 8:00 am • Palm 5

Bayer Satellite Symposium (not CME Eligible)

See page 15 for more information.

- **Xofigo (radium Ra 223 dichloride): 6 Facts on Identifying Appropriate Patients**
Steven Finkelstein MD, FACRO & Rodney Ellis MD

7:00 - 8:00 am • Palm 2-3-4

Breakfast in Exhibit Hall

7:00 am - 12:00 pm • Palm 2-3-4

Exhibits Open8:00 - 9:30 am • Palm 1 • **FREE SAM****Exploring the Changing Landscape for High-Risk and Advanced Prostate Cancer**

Moderators: Jason Efstathiou, Steven Finkelstein

- **Update on Radiotherapy in High-Risk Prostate Cancer: Staging, Dose, Volume, and Androgen Deprivation**
Daniel Hamstra – University of Michigan, Ann Arbor, MI
- **Introduction of Technology in Cooperative Group Trials: Prostate Cancer as a Paradigm**
Jeff Michalski – Washington University School of Medicine, St. Louis, MO
- **Role of Radiotherapy in OligoMetastatic Prostate Cancer: Current State & Future Directions**
Neha Vapiwala – University of Pennsylvania, Philadelphia, PA

9:30 - 10:15 am • Palm 2-3-4

Exhibits/Break10:15 - 11:45 am • Palm 1 • **FREE SAM****Evolving Paradigms in Treating Breast Cancer With Radiotherapy**

Moderator: Tarita Thomas

- **Management of the Axilla in the Modern Era**
Jonathan Strauss – Northwestern Medicine, Chicago, IL
- **Radiation Issues Following Neoadjuvant Chemotherapy in Breast Cancer**
Bruce Haffty – Rutgers Cancer Institute, New Brunswick, NJ
- **Altered Fractionation in Early Stage Breast Cancer**
Asal Rahimi – University of Texas Southwestern, Dallas, TX

12:00 - 1:00 pm • South Ballroom

Lunch with Presentations: CEO Vision for the Future (not CME Eligible)

Moderators: Arno Mundt, Sheila Rege

Hosted by Varian Medical Systems and Elekta

- **Industry CEOs Share Their Vision of the Future; Innovative or Disruptive Threats to Radiation Oncology**
Dow Wilson MBA – Varian Medical Systems, Palo Alto, CA
Richard Hausmann PhD – Elekta, Stockholm, Sweden

◀ FRIDAY CONTINUED

1:15 - 1:45 pm • Palm 1

The Life and Legacy of Dr. Luther Brady

Moderator: Eduardo Fernandez

Sucha Asbel – Cooper University Health Care, Mount Laurel, NJ
Joanne Dragun – 21st Century Oncology, Jacksonville, FL
Dennis Galinsky – Berwyn Radiation Oncology, Berwyn, IL

1:45 - 2:15 pm • Palm 1

Keynote Address

- **The Future of Cancer Management**
Richard Levy PhD – Palo Alto, CA

2:15 - 2:45 pm • Palm 1

ACRO Awards Ceremony

- **Gold Medal Award Presentation**
- **Installations of New Fellows**
- **Presentations of Outstanding Abstract Awards**

2:45 - 3:00 pm • Palm 1 Foyer

Break

3:00 - 5:00 pm • Palm 1

The Business & Economics of Radiation Oncology Practice

Moderator: William Noyes

- **ACRO Government Relations & Economics Committee Update**
Sheila Rege – Northwest Cancer Clinic, Kennewick, WA
Jason McKittrick – Liberty Partners Group, Washington, DC
- **Dr. David Krause Washington Update**
Andrew Woods – Liberty Partners Group, Washington, DC
- **Practical Application of Coding Updates and Documentation of Your Practice**
Ron DiGiaimo – Revenue Cycle Inc., Austin, TX
- **ACRO Accreditation Update**
Jaroslav Hepel – Brown University, Providence, RI

2:45 - 5:15 pm • Narcissus/Orange

Resident Symposium

- **ACRO Resident HIT and GROW Presentations**
Global Radiation Oncology Workforce (GROW) Experience
Lauren Kropp – Pacific Cancer Institute, Wailuku, HI
Lindsay Puckett – Medical College of Wisconsin
Heidelberg Ion Therapy (HIT) Experience
Jacqueline Kelly – Yale School of Medicine, New Haven, CT
- **Career / Interview Advice - Panel Discussion**
Moderator: Courtney Hentz
Catheryn Yashar – University of California San Diego, La Jolla, CA
Jonathan Strauss – Northwestern Medicine, Chicago, IL
Robert Amdur – University of Florida, Gainesville, FL
Faculty Panel Discussion
– **Arno Mundt, Jonathan Strauss, Robert Amdur**
 - How to master your rotations – advice from faculty on how to be an outstanding resident
 - How to start the job hunt
 - Review resources, how to draft a cover letter and construct a CV
- **Interview Advice**
 - What makes a candidate stand out in your mind?
 - ASTRO interviews
- **Practice Cases with the Experts**
Residents rotate around the room with 10+ disease site-specific attendings, running through patient cases in a Q&A format with feedback and advice from attendings.

Robert Amdur – H & N
Parul Barry – GYN and Breast
Jason Efstathiou – GU
Matthew Harkenrider – GYN and Lung
Brian Lally – Lung
Shannon MacDonald – Lymphoma
Arno Mundt – GYN
Suneel Nagda – Breast
Brandi Page – H&N
Abhishek Solanki – GU
Jonathan Strauss – Breast
Tarita Thomas – GI
Stephanie Weiss – CNS

FRIDAY CONTINUED

5:15 - 7:15 pm • Narcissus/Orange

New Practitioner & Resident Symposium / MEET featuring Quizzo (not CME Eligible)

Quizmasters: Parul Barry, Anthony Dragan, Courtney Hentz, Brian Lally, Brandi Page

Refreshments hosted by Revenue Cycle

The purpose of these two events is to have fun in an entertaining environment.

- **The MEET (Meet Excellent Educators & Teachers)**
This is a speed networking event. Individuals will spend 4-5 minutes meeting various faculty for 4-5 rounds.
- **ROQ (Radiation Oncology QUIZZO)**
We will use the fun Quizzo trivia format for this section of the evening. Faculty will serve as team captains. Teams work together to solve a series trivia questions. There will be prizes!

5:15 - 6:45 pm • Poinsettia

Government Relations & Economics Committee Meeting

6:00 - 7:00 pm • Palm 5

Varian Satellite Symposium (not CME Eligible)

See page 15 for more information.

- **From Whole Brain to HyperArc for Brian Metastases: Recent Outcomes**
Evan Thomas MD, PhD
- **Gantry-Based SBRT for Prostate Cancer: Outcomes of a Large Multi-Institutional Study**
Constantine Mantz MD

7:00 - 8:00 pm • Poolside (Palm 2-3-4 if rainy)

President's Reception

- All conference attendees are welcome to enjoy a festive reception with complimentary appetizers and beverages.

SATURDAY, MARCH 9

7:30 am - 2:00 pm • Outside Palm 1

Registration Open

7:30 - 9:00 am • Narcissus/Orange

Resident & New Practitioner Symposium - "Street Smarts" (not CME Eligible)

Moderators: Parul Barry, Courtney Hentz

Breakfast hosted by SunTrust

7:30 - 7:55 am

- **Insurance Topics and Managing Debt**
 - Disability, Life, Malpractice insurance
 - Financial Advice – buying a home, setting up retirement funds
 - Managing Medical school debt
 - Speakers: **Carol Hakemian** – MassMutual, **Tom Callahan** – Sun Trust

8:00 - 8:25 am

- **Starting a Practice/Excelling in Your Career**
 - Private practice – establishing referral patterns
 - Academics – excelling in research endeavors: grant funding, finding mentor, etc
 - Speakers: **Abhishek Solanki** – Loyola University Medical Center, Maywood, IL, **Catheryn Yashar** – University of California San Diego, La Jolla, CA, **Ben Wilkinson** – Provision Center for Proton Therapy, Knoxville, TN

8:30 - 9:00 am

- **Work-Life Balance**
 - Work life balance
 - Having a family in medicine
 - Speakers: **Jessica Schuster** – University of Wisconsin, Madison, WI, **Neha Vapiwala** – University of Pennsylvania, Philadelphia, PA

8:00 - 9:00 am • Palm 5

Novocure Satellite Symposium (not CME Eligible)

See page 15 for more information.

- **TTFields and the Radiation Oncologist**
Volker Stieber MD

8:00 - 9:00 am • Veranda Room

Scientific Program Committee Meeting

◀ SATURDAY CONTINUED

8:00 am - 1:30 pm • Palm 2-3-4

Posters Displayed9:00 - 10:15 am • Palm 1 • **FREE SAM****Challenging Topics in Head and Neck Cancer**

Moderator: J. Nicholas Lukens

- **Postop Oral Cavity Cases**
Robert Amdur – University of Florida, Gainesville, FL
- **Managing Toxicity in Head and Neck Cancer Patients**
Brandi Page – Johns Hopkins Medicine, Bethesda, MD

10:15 - 10:45 am • Palm 2-3-4

Break with Posters10:45 am - 12:00 pm • Palm 1 • **FREE SAM****Curing Endometrial Cancer, One Gray at a Time**

Moderators: Parul Barry, Neil Taunk

- **Adjuvant Radiotherapy for Early Stage Endometrial Cancer: Beyond the Risk Groups**
Matthew Harkenrider – Loyola University, Maywood, IL
- **Adjuvant Treatment in Endometrial Cancer: Clarity or Confusion?**
Marcus Randall – University of Kentucky, Lexington, KY
- **Challenging Cases in Endometrial Cancer**
Catheryn Yashar – University of California San Diego, La Jolla, CA

12:00 - 1:30 pm • Palm 2-3-4

Lunch with Posters/Poster Walk (not CME Eligible)

Moderators: Steven Feigenberg, Brandi Page

- **Radio-Sensitizing Effects of Mutant p53 Reactivating Drug APR-246 in Head and Neck Cancer**
Anatoly Nikolaevⁱ, Ling Zengⁱ, James A. Bonnerⁱ, Sharon Spencerⁱ, Eddy S. Yangⁱ
ⁱ University of Alabama at Birmingham, Birmingham, AL
- **Pathogenic Germline Variants in a Patient With Severe Fibrosis and Cardiac Toxicity from Breast Radiotherapy**
Tyler Wilhite, MDⁱ, Ryan Youlandⁱ, Shulan Tianⁱ, Randi Finleyⁱ, Jann Sarkariaⁱ, Kimberly Corbinⁱ
ⁱ Mayo Clinic, Rochester, MN

- **Megavoltage versus Kilovoltage CT Planning for Definitive Prostate Brachytherapy**
Thomas Hunterⁱ, Bhaswanth Dhaniredyⁱ, Stephen Strupⁱ, William St. Clairⁱ
ⁱ University of Kentucky, Lexington, KY
- **Persistent [18F] Fluorodeoxyglucose Positron Emission Tomography Avidity after Definitive Radiotherapy and Outcome in Ewing Sarcoma and Rhabdomyosarcoma**
Alexander Sherryⁱ, Joshua Andersonⁱ, Marques Bradshawⁱⁱ, David Whartonⁱⁱ, Christopher Brettⁱⁱ, Dominique Delbekeⁱⁱ, Eric Shinoharaⁱⁱ, Scott Borinsteinⁱⁱ
ⁱ Vanderbilt University School of Medicine, Nashville, TN
ⁱⁱ Vanderbilt University Medical Center, Nashville, TN
- **Grade and Lymphovascular Space Invasion are Significant Predictors of Lymph Node Involvement in Stage II Endometrial Adenocarcinoma**
Eric Andersonⁱ, Mark Sittigⁱ, Mitchell Kamravaⁱ
ⁱ Cedars-Sinai Medical Center, Los Angeles, California, USA
- **Patterns of Failure and Toxicity Profile for Stereotactic Body Radiation Therapy of Nodal Recurrent Head and Neck Squamous Cell Carcinoma**
Clark M Hathewayⁱ, Brian J Gebhardtⁱ, James P Ohrⁱⁱ, M. Saiful Huqⁱ, Robert L Ferrisⁱⁱⁱ, Dwight E Heronⁱ, David A Clumpⁱ
ⁱ Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA
ⁱⁱ Department of Medicine, Division of Medical Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA
ⁱⁱⁱ Department of Otolaryngology, Head and Neck Surgery, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA

12:30 - 1:30 pm • Palm 5

Locum Tenens Forum

- Pick up your lunch at the buffet in Palm 2-3-4 before joining your locum tenens colleagues for a networking lunch in Palm 5.

1:30 - 2:45 pm • Palm 1 • **FREE SAM****Lymphoma in Adults, Adolescents and Children**

Moderators: Parul Barry, Shannon MacDonald

- **Lymphoma Hi-Lo: Playing Your Cards Right with Radiation Dose**
Karen Winkfield – Wake Forest University, Winston-Salem, NC
- **How Management of Pediatric Hodgkin's Lymphoma Differs from Adults**
Shannon MacDonald – MGH/Harvard University, Boston, MA

2:45 - 3:00 pm • Palm Foyer

Break

◀ SATURDAY CONTINUED

3:00 - 4:15 pm • Palm 1 • **FREE SAM****Sarcoma in Adults, Adolescents and Children**

Moderators: Sara Alcorn, Shannon MacDonald

- **Radiotherapy for Pediatric and Adult Sarcoma: The Past and Future**
Bree Eaton – Emory University, Atlanta, GA
- **Treatment Planning Techniques for Challenging Sarcoma Cases**
Shannon MacDonald – MGH/Harvard University, Boston, MA

4:15 - 5:30 pm • Palm 1

Oral Presentations

Moderators: Sara Alcorn, Jessica Schuster

- **Deep Convolutional Neural Networks for Automatic Segmentation of the Hippocampus on MRI Scans**
Charles Vuⁱ, Evan Porterⁱ, Patricia Fuentesⁱⁱ, Thomas Guerreroⁱ
ⁱ Beaumont Health, Royal Oak, MI
ⁱⁱ Oakland William Beaumont School of Medicine, Rochester, MI
- **A Prospective Evaluation of Whole Brain Volume Loss and Neurocognitive Decline Following Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer**
Chengcheng Guiⁱ, Namrata Chintalapatiⁱ, Russell Halesⁱ, Ranh Voongⁱ, Haris Sairⁱⁱ, Jimm Grimmⁱ, Mario Duhonⁱ, Lawrence Kleinbergⁱ, Tracy Vannorsdallⁱⁱⁱ, Kristin Redmondⁱ
ⁱ Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD
ⁱⁱ Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD
ⁱⁱⁱ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD

- **Placement and Repositioning of Tumor-Treating Field Arrays do not Alter Target Volume Coverage for Glioblastoma Radiotherapy**
Gregory Stachelekⁱ, Jimm Grimmⁱ, Kristin Redmondⁱ, Michael Limⁱ, Chetan Bettegowdaⁱ, Lawrence Kleinbergⁱ
ⁱ Johns Hopkins Hospital, Baltimore, MD, USA
- **Echo-Planar MR Spectroscopic Imaging Pre- and Post-Radiotherapy in Patient with High Grade Glioma: Correlation with Survival**
Christen Elledge, MDⁱ, Doris Lin, MD, PhDⁱⁱ, Yanqin Lin, PhDⁱⁱⁱ, Karim Snoussi, PhDⁱⁱ, Anouk Marsman, PhDⁱⁱ, Andrew Maudsley, PhD^{iv}, Sulaiman Sheriff, MS^{iv}, Katie Link, BSⁱⁱ, Peter Barker, DPhilⁱⁱ, Lawrence Kleinberg, MDⁱ
ⁱ Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
ⁱⁱ Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD
ⁱⁱⁱ Department of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance, Xiamen, Fujian, China
^{iv} Department of Radiology, Miller School of Medicine, University of Miami, Miami, FL
- **Preoperative Versus Postoperative Radiosurgery - Differences in Target Delineation**
Chase Hansen, Eddie Zhang, Vladimir Avkshtol, Jonathan Paly, Karen Wong, Douglas Lee, Nina Burbure, Jiangtao Gou, Xiaoming Chen, Sameera Kumar, Scott Shepard, Shelly Hayes, Stephanie Weiss
ⁱ Fox Chase Cancer Center, Philadelphia, PA, USA

5:30 pm

ACRO 2019 Adjourns

Sheila Rege MD, FACRO, President

5:30 - 7:30 pm • Narcissus

ACRO Board of Chancellors Meeting

INDUSTRY SPONSORED

Satellite Symposium Sessions

Sessions are held in Palm 5 and are not for CME.

VIEWRAY

Thursday, March 7 • 12–1pm

- Speaker:** Michael Chuong MD
Radiation Oncologist
Miami Cancer Institute
- Title:** ViewRay MRIdian Linac: From Startup to On-table Adaptive Cases
- Description:** Dr. Chuong will describe the initial MRIdian Linac experience at Miami Cancer Institute including patient selection, early clinical outcomes, techniques to improve treatment efficiency, and online adaptive applications.

SIRTEX

Thursday, March 7 • 6:30 –7:30pm

- Speaker:** Andrew Kennedy MD
Physician in Chief, Radiation Oncology
Director, Radiation Oncology Research
Sarah Cannon, Nashville, TN
- Title:** Use of Y-90 Alone and With External Beam Radiotherapy for Unresectable Hepatic Tumors
- Description:** Dr. Kennedy will discuss a multimodality approach to radiation therapy to effectively treat tumors resulting from colorectal cancer.

BAYER

Friday, March 8 • 7–8am

- Speaker:** Steven Finkelstein MD, FACRO and
Rodney Ellis MD
- Title:** Xofigo (radium Ra 223 dichloride): 6 Facts on Identifying Appropriate Patients
- Description:** Treatment for advanced prostate cancer.

VARIAN MEDICAL SYSTEMS

Friday, March 8 • 6–7pm

- Speaker:** Evan Thomas MD, PhD
University of Alabama @ Birmingham
Birmingham, AL
- Title:** Featured Updates: From Whole Brain to HyperArc for Brain Metastases: Recent Outcomes
- Speaker:** Constantine Mantz MD
21st Century Oncology
Fort Myers, FL
- Title:** Featured Updates: Gantry-Based SBRT for Prostate Cancer: Outcomes of a Large Multi-Institutional Study

NOVOCURE

Saturday, March 9 • 8–9am

- Speaker:** Volker Stieber MD
Director, Neuro-Oncology Tumor Board
Medical Director, Stereotactic Radiation Therapy
Novant Health Forsyth Medical Center
Derrick L. Davis Cancer Center
Winston-Salem, NC
- Title:** TTFields and the Radiation Oncologist
- Description:** Dr. Volker Stieber will review TTFields MOA, its efficacy and safety in GBM, and discuss why radiation oncologists play a pivotal role treating patients with Optune®.

CORPORATE SUPPORTERS

Platinum Level	  	 
Gold Level		
Silver Level		


Thank you to Mevion for establishing the Outstanding Abstract Award.

Prizes for the top three submitted abstracts will be presented at the award ceremony on Friday afternoon, March 8.

SCHEDULE

Thursday March 7	Exhibition Hall Opens..... 10:00 am Exhibits/Break..... 10:00-10:40 am Exhibits/Break..... 2:45-3:30 pm Exhibition Hall Closes.....5:00 pm	Friday March 8	Exhibition Hall Opens..... 7:00 am Breakfast in Exhibit Hall 7:00-8:00 am Exhibits/Break..... 9:30-10:15 am Exhibition Hall Closes 12:00 pm
---------------------	---	-------------------	--

EXHIBITOR FLOOR PLAN





Your Expert Oncology Resource

The Revenue Cycle Coding Strategies team identifies practical ways to streamline radiation oncology reimbursement, cut operational costs, maintain compliance with federal regulations and provide education to improve profitability.

Consulting Services

- Billing, Coding and Compliance Reviews
- Remote Charge Capture Solutions
- Electronic Health Record (EHR) Analysis and Solutions
- Revenue Cycle Management Solutions
- Client Resource Center
- On-site Training and Education

Education and Support

- Navigators® - Coding and Compliance Reference Guides with Authoritative Guidance
- Online Training Courses
- CROWN® Seminars - Get the most comprehensive coding and compliance training and earn CEUs
- Webinars: Live and On Demand

www.revenuecycleinc.com | 512.583.2000 | www.codingstrategies.com



We are medical billing specialists.

Providing customized services and medical billing solutions for hospital-based practices and freestanding facilities, RC Billing® leads the way in maximizing revenues for today's medical and radiation oncology specialists.

- Enhanced profitability
- Industry-best billing expertise
- Clinical experience
- Proven performance

RC Billing® is the solution; the ideal business-side partner for high-performance medical and radiation oncology physicians and group practices.

512.583.2000 | www.rcbilling.com



Platinum Supporter 21st Century Oncology 22

www.21co.com



A premier nationwide provider of integrated cancer care. The largest radiation oncology provider and one of the largest groups of urologists in the U.S. Headquartered in Ft. Myers, Florida, the physician-led company operates in 17 states, 7 countries, with a network of over 300 locations, including 150 radiation therapy facilities.

Accuboot 8

www.accuboot.com



AccuBoost is a non-invasive breast brachytherapy treatment approach using mammographic imaging to conformally target the tumor bed for 5 or 10 day APBI and Boost.

ACRO Accreditation Programs and Membership Information 25

www.acro.org



The American College of Radiation Oncology is the essential, professional society for success in the day-to-day practice of radiation oncology. Since 1990, ACRO has focused its attention on both the clinical and economic aspects of practicing radiation oncology. As a professional medical society of doctors representing a relatively small subspecialty, ACRO has led the effort to ensure appropriate reimbursement for clinical care and has provided services to help its members become better clinicians. ACRO's mission is to strive to ensure the highest quality care for radiation therapy patients and promote success in the practice of radiation oncology through education, responsible socioeconomic advocacy, and integration of science and technology into clinical practice. ACRO serves as THE society for radiation oncologists in the United States. Whether it is fostering the next generation of radiation oncologists, developing the talents of current physicians, or ensuring your clinic practices the highest quality of care, we are here to help.

Accuray, Inc 34

Augmenix/ Boston Scientific 26

www.spaceoar.com



SpaceOAR® hydrogel is a prostate-rectum spacer that separates and protects the rectum during prostate radiotherapy, decreasing rectal toxicity and minimize changes in quality of life. SpaceOAR hydrogel is FDA cleared, CE marked, approved in Australia and Japan and licensed in Canada. Augmenix was recently acquired by Boston Scientific.

Gold Supporter Bayer 16

www.bayer.us/



Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.

Best Medical International 7

www.teambest.com/



TeamBest includes over a dozen companies offering complementary products and services for brachytherapy, health physics, radiation oncology, blood irradiation, vascular therapy, imaging, and medical particle acceleration. TeamBest is the single source for an expansive line of life saving medical equipment and supplies. Our trusted team is constantly expanding and innovating to provide the most reliable and cutting edge medical equipment and supplies to the global healthcare and research industries.

Blue Earth Diagnostics, Inc. 10

www.blueearthdiagnostics.com



Blue Earth Diagnostics, Inc. is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management for cancer patients. Its first product, Axumin® (fluciclovine F 18), was approved by the FDA in May 2016. For more information, please visit www.axumin.com.

Brainlab 14

www.brainlab.com



Brainlab develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments. Brainlab technology powers treatments in radiosurgery as well as neurosurgery and other surgical fields.

CIVCO Radiotherapy 28




www.CivcoRT.com



CIVCO Radiotherapy has over 35 years of experience in the radiation oncology industry and offers the largest breadth of high-quality, innovative, patient-centric radiotherapy solutions. These solutions include couchtops and overlays for linear accelerators and imaging systems, advanced patient immobilization solutions, robotic patient positioning, advanced fiducial markers, and immobilization/positioning equipment and consumables.



**Patient-Specific,
3D Printed Bolus**

-  Uniform Thickness Bolus
-  Brachytherapy Applicator
-  Modulated Electron Bolus



**Body Pro-Lok ONE™
SBRT Immobilization**



The only SBRT bridge that features lateral and tilting offset with variable height adjustment capability.

**Solstice™ SRS
Immobilization System**



Provides corrective pitch capability and positioning flexibility with non-invasive head immobilization.

Improving the Patient Journey

Visit CIVCO's ACRO Booth #28 to learn about our exciting, new collaborations and solutions that improve the entire patient journey. CIVCO is committed to providing a better way, from planning to post-treatment care.

info@CivcoRT.com | www.CivcoRT.com

COPYRIGHT © 2019. CIVCO IS A REGISTERED TRADEMARK OF CIVCO MEDICAL SOLUTIONS. BODY PRO-LOK ONE AND SOLSTICE ARE TRADEMARKS OF CIVCO. ALL OTHER PRODUCTS ARE PROPERTY OF THEIR RESPECTIVE OWNERS. ALL PRODUCTS MAY NOT BE LICENSED IN ACCORDANCE WITH CANADIAN LAW. 2018A1424 REV. A



PUT GBM ON **PAUSE**



In patients with newly diagnosed GBM,
OPTUNE® + TMZ HAS BEEN PROVEN TO

Survival with Optune + TMZ vs TMZ alone was significantly higher at the 2-year landmark analysis and remained higher at 5 years¹



- Median OS was significantly extended with Optune—by nearly 5 months ($P < 0.001$)¹
- Optune + TMZ also significantly improved PFS vs TMZ alone (median PFS: 6.7 months vs 4.0 months, $P < 0.001$)¹

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Selected Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

PUT LIFE ON PLAY

Marcia is an Optune user.

BT is Marcia's husband and caregiver, and Juliet is their daughter.

PROVIDE LONG-TERM QUALITY SURVIVAL^{1,2}

Patients treated with Optune + TMZ maintained QoL over time^{2,3}

Both HCPs and patients reported stable QoL evaluation scores up to 1 year of Optune use

- HCP-reported KPS* was approximately 90 at baseline and 12 months³
- Patient-reported Global Health Status[†] was approximately 70 at baseline and 12 months²

*HCP-reported data collected per Karnofsky Performance Score (KPS) assessment at baseline and then repeated monthly. Patient functional status via KPS (at multiple time points) measured patient independence in activities of daily living.

[†]Patient-reported data collected per EORTC QLQ-C30 at baseline and Months 3, 6, 9, and 12. This 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).

EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; GBM, glioblastoma; OS, overall survival; PFS, progression-free survival; QoL, quality of life; TMZ, temozolomide.

References: 1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA*. 2017;318(23):2306-2316. 2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. *JAMA Oncol*. 2018;4(4):495-504. 3. Zhu J-J, Demireva P, Kanner AA, et al. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. *J Neurooncol*. 2017;135:545-552.

Please see the following Important Safety Information for Optune and visit Optune.com/IFU for Optune Instructions For Use for complete information regarding the device's indications, contraindications, warnings, and precautions.

Go to Optune.com to learn even more about putting GBM on pause and life on play

Patient image reflects the health status of the patient at the time the photo was taken.

novocure[™]

OPTUNE[®]
Elevate Expectations

Indications For Use

Optune® is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information**Contraindications**

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure™ (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Please visit Optune.com/IFU for Optune Instructions For Use for complete information regarding the device's indications, contraindications, warnings, and precautions.

**Platinum Supporter
Elekta****19**www.Elekta.com

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

Elsevier PracticeUpdate**30**www.practiceupdate.com**IBA****11**www.iba-worldwide.com/proton-therapy

IBA is the worldwide leader in proton therapy technology. The company has been leading proton therapy for the last 30 years and has built the largest user community of world's best proton therapy centers. IBA focuses on bringing integrated and innovative solutions for the diagnosis and treatment of cancer and is the worldwide technology leader in the field of proton therapy. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers or compact, single room solutions.

Medtronic**27**www.medtronic.com

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic, and economic expertise to address the complex challenges faced by healthcare systems today. Let's take healthcare Further, Together. Learn more at Medtronic.com.

Mevion Medical Systems**31**www.mevion.com**MIM Software, Inc.****9**www.mimsoftware.com

MIM® offers practical solutions and timesavings for radiation oncology through atlas segmentation, deformable dose accumulation, deformable alignment of PET/CT, and adaptive re-contouring. MIM Assistant® provides powerful automation of clinical tasks. MIMcloud® and MIM Zero Footprint offer secure and remote access, allowing users to run MIM anywhere, without VPN, via the internet.

**Platinum Supporter
Novocure Inc.****2**www.novocure.com

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFIELDS, which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFIELDS in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure

Proton Therapy Partners**33****Radiating Hope****15**www.radiatinghope.org

Radiating Hope is a nonprofit 501(c)(3) organization. Our mission is to improve cancer care, specifically radiation oncology care, around the globe. We do this by donating needed equipment to developing areas and by providing training and education from our volunteer medical professionals. Our goal is to improve access to cancer care for all who need it, regardless of where they live.

Raysearch Americas. 24www.raysearchlabs.com**ADVANCING CANCER TREATMENT**

RaySearch is a committed pioneer of oncology software. Since 2000, we have worked in close cooperation with leading centers to improve life and outcomes for patients. Our systems use groundbreaking automation and machine learning to create new possibilities for care and to increase efficiency for our customers and partners. And this is just the beginning.

Rejûvaskin 29www.rejuvaskin.com

Rejûvaskin is a skin healing company dedicated to providing high quality, effective products that address unique skincare needs. Knowing the damage incurred by cancer treatments, Rejûvaskin has developed a range of products to help maintain your patients' skin health as they undergo these lifesaving therapies and procedures. Revive Skin Recovery Cream was created with your patients in mind to help fortify, soothe, and revitalize skin damaged by radiation therapy. Rejûvaskin also features the Scar Heal family of products, recommended by physicians around the world to target unwanted scarring. As a skin healing company, Rejûvaskin is here to help ensure your patients maintain healthy skin throughout their treatment; because healthy skin is always in.

**Silver Supporter
Revenue Cycle Inc. 1**www.revenuecycleinc.com

Revenue Cycle provides oncology consulting services and educational resources to hospital-based, private practice or freestanding cancer center healthcare providers. Our services include medical record reviews, compliance, education and training, billing and coding, remote solutions and revenue cycle management solutions. Let us identify ways to streamline reimbursement, cut operational costs, maintain compliance and improve profitability.

Sensus Healthcare 12www.sensushealthcare.com

At Sensus Healthcare, we are devoted to making a difference in the lives of people who suffer from non-melanoma skin cancer and unsightly keloid scarring. By designing and manufacturing safe and reliable state-of-the-art Superficial Radiation Therapy technology right here in the United States, we are providing compassionate dermatologists and oncologists around the world with a non-surgical treatment option that empowers them to cure patients without compromising patient confidence, dignity or quality of life.

**Gold Supporter
Sirtex 21**www.sirtex.com

Sirtex Medical develops and delivers interventional oncology treatments using novel small particle technology to improve outcomes for patients with metastatic colorectal cancer (mCRC). SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation via the hepatic artery during Selective Internal Radiation Therapy (SIRT). Recent SIRFLOX Study data showed a statistically significant improvement of 7.9 months in median Progression-Free Survival in the liver for patients with unresectable mCRC treated first line with SIR-Spheres Y-90 resin microspheres plus standard chemotherapy.

Springer Publishing 32www.springerpub.com**Platinum Supporter
Varian 17**www.varian.com

Varian is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. We partner with physicians, scientists, researchers and others around the world to offer the most advances and cost-effective treatment technologies available.

**Platinum Supporter
ViewRay, Inc 4**www.viewray.com

ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


Visionrt 6www.visionrt.com

The leader in Surface Guided RT (SGRT), Vision RT, creates technology for Surface Guided Radiation Therapy. This technique allows patients to be positioned and monitored during radiation treatment using optical surface guidance. Widely used on all treatment sites, SGRT particularly benefits left breast cancer treatment by avoiding cardiac damage, and aids in both comfort and speed during brain treatments. Visit www.visionrt.com to learn more.

Wolters Kluwer 13www.lww.com

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. Our solutions are designed to help professionals build clinical competency and improve practice so that healthcare organizations can succeed in value-based care delivery models. Product solutions include Lippincott, Ovid®, and UpToDate®.

HILTON ORLANDO LAKE BUENA VISTA



SAVE THE DATE!

RADIATION ^{The} ONCOLOGY

SUMMIT

February

ACRO 2020

27-29

Westin Ft. Lauderdale Beach Resort

Ft. Lauderdale, Florida

The Radiation Oncology Summit
February 27-29, 2020

ACRO



American College of
RADIATION ONCOLOGY
Integrating Science and Technology into Patient Care

For more information visit www.acro.org

Please come by our booth in the exhibit hall to discuss your accreditation needs.

Patients First
*Our Focus is Radiation
Oncology Safety!*



Online Case Review
Expert Panel - Comprehensive

Smart Submission
Guided - Efficient - Compliant



Protect Your Patients and Practice -Get Accredited- Call ACRO 206.956.3642 Today!

As part of its mission as the “essential professional society for success in the day-to-day practice of radiation oncology,” the American College of Radiation Oncology developed a program in 1995 to accredit radiation oncology practices. The goal: to equip radiation oncologists with a powerful tool to proactively protect patients, manage risk, and review practices from top to bottom. Since then, ACRO Accreditation has undergone periodic revisions to reflect clinical and scientific advances within the field. In October 2010, ACRO Accreditation emerged from an extensive administrative review with an updated and intuitive Web-based accreditation system, powered by Equal-Estro. This new system features:

- ▶ unbiased, blind, online case reviews by a disease site specific panel of experts
- ▶ smart 100% electronic compliant submission of case files
- ▶ 100% focus on radiation oncology

FEES

\$8,750 | Principal Practice Fee

- ▶ Practice headquarters
- ▶ Travel fees for onsite reviews will apply

\$3,500 | Additional Practice Fee

- ▶ Additional office within the same practice (Max. 2)

FOR MORE INFORMATION

For more information about ACRO and the accreditation program please call 206.956.3642 or visit acro.org.



2001 6th Ave, Suite 2700
Seattle, WA 98121
PH 206.956.3642
EM info@acro.org WB acro.org